SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/30/2026 11:07 PDT] SeaStar Medical Holding Corporation (NASDAQ:ICU), Down By 100% ($4.22) From $4.22 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/21/2026 11:07 PDT] SeaStar Medical Holding Corporation (NASDAQ:ICU), Down By 100% ($4.92) From $4.92 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/17/2026 06:31 PDT] ICU Expected to Trade Down After Bearish Patterns Develop
• [07/06/2026 06:49 PDT] ICU Expected to Trade Down After Bearish Patterns Develop
• [07/01/2026 11:07 PDT] SeaStar Medical Holding Corporation (NASDAQ:ICU), Up By 100% ($3.12) From $3.12 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/29/2026 06:11 PDT] ICU Expected to Trade Up After Bullish Patterns Develop